According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
A number of other research firms have also commented on GRFS. JPMorgan Chase & Co. lowered Sogou from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $5.50 to $4.12 in a research report on Thursday, June 27th. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Three research analysts have rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $20.75.
GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, meeting analysts’ consensus estimates of $0.25. GRIFOLS S A/S had a return on equity of 15.49% and a net margin of 12.35%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. On average, analysts forecast that GRIFOLS S A/S will post 1.27 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in GRFS. Deutsche Bank AG boosted its position in shares of GRIFOLS S A/S by 670.3% during the 4th quarter. Deutsche Bank AG now owns 12,427,277 shares of the biotechnology company’s stock valued at $228,164,000 after purchasing an additional 10,813,901 shares in the last quarter. Norges Bank bought a new stake in shares of GRIFOLS S A/S during the 4th quarter valued at about $57,748,000. JPMorgan Chase & Co. boosted its position in shares of GRIFOLS S A/S by 856.0% during the 1st quarter. JPMorgan Chase & Co. now owns 1,558,478 shares of the biotechnology company’s stock valued at $31,340,000 after purchasing an additional 1,395,461 shares in the last quarter. FIL Ltd boosted its position in shares of GRIFOLS S A/S by 12.2% during the 1st quarter. FIL Ltd now owns 8,170,942 shares of the biotechnology company’s stock valued at $164,318,000 after purchasing an additional 887,474 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its position in shares of GRIFOLS S A/S by 1,557.5% during the 4th quarter. Impax Asset Management Group plc now owns 482,189 shares of the biotechnology company’s stock valued at $8,853,000 after purchasing an additional 453,098 shares in the last quarter. Institutional investors own 19.01% of the company’s stock.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Article: Oversold
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.